Role of serum markers in diagnosis of exacerbations of sarcoidosis

   In order to improve the diagnosis of exacerbation and activity of sarcoidosis in patients receiving complex treatment, including corticosteroids, 303 patients with respiratory sarcoidosis were examined at the initial visit (before treatment) and every 2 months of treatment for 2 years. Group 1–193 patients without exacerbation of sarcoidosis; group 2–51 patients with exacerbation of sarcoidosis, who did not take corticosteroids (GCS); group 3–59 patients with exacerbation of sarcoidosis, long-term taking corticosteroids. In order to improve the diagnosis of exacerbation and activity of sarcoidosis in patients receiving complex treatment, including glucocorticosteroids, 303 patients with respiratory sarcoidosis were examined at the initial visit (before treatment) and every 2 months of treatment for 2 years. Group 1–193 patients without exacerbation; group 2–51 patients with exacerbation who did not take corticosteroids (GCS); group 3–59 patients with exacerbation, long-term taking corticosteroids. Conducted clinical and biochemical blood tests, computed tomography of the respiratory organs, spirography, echocardiography, electrocardiography at rest. Changes in the following serum markers were studied: free radicals (RwR), resistance to oxidative stress calculated by trolox equivalent (UcE), angiotensin-converting enzyme (ACE), adenosine deaminase (ADA), the correlation coefficient (CC) was calculated according to the developed formula (patent): CC = ACE/ADA in arbitrary units (KKnorm = 1.2–2.4), markers of lipid metabolism disorders were determined, to assess the activity of endogenous inflammation, the indicator of lipoidosis activity (PAL) was calculated according to the previously developed formula (patent): PAL = TC/LDLxc + TGL. Before treatment, 100 % of patients with sarcoidosis showed signs of moderate endogenous inflammation, an active granulomatous process, hypoxemia, and a decrease in the body’s antioxidant defense. The sensitivity of the serum adenosine deaminase (ADA) enzyme in exacerbations of sarcoidosis was 31 %, and the specificity was 48 %. The correlation coefficient (CC) had a sensitivity of 85.0 %; specificity 78.8 %; diagnostic efficiency of 80.0 % and higher clinical value than ACE, ADA, PAL, SVR, UKO. Thus, the serum enzyme adenosine deaminase (ADA) should be included in the mandatory minimum of laboratory methods in patients with sarcoidosis.

1. Sarcoidosis. Clinical recommendations, ed. ON THE. Mukhina, Moscow: IMA 150 PRESS. 2009; 128 p.

2. Martusewicz-Boros M.M. [et al.]. What comorbidities accompany sarcoidosis? A large cohort (n = 1779) patients’ analysis. Sarcoidosis, vasculitis, and diffuse lung diseases: Official Journal of WASOG. 2015; 2 (32): 115–20.

3. Lieberman J. Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. The American Journal of Medicine.1975; 3 (59): 365–72.

4. Lieberman J. [et al.]. Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. The American review of respiratory disease. 1979; 2 (120): 329–35.

5. Rømer F. K., Jacobsen F. The influence of prednisone on serum angiotens in converting enzyme activity in patients with and without sarcoidosis. Scandinavian Journal of Clinical & Laboratory Investigation.1982; 4 (42): 377–382.

6. Lynch J. P., Kazerooni E. A., Gay S. E. Pulmonary sarcoidosis. Clinics in chest medicine.1997; 4 (18): 755–85.

7. Sheffield E. A. Pathology of sarcoidosis. Clinics in chest medicine.1997; 4 (18): 741–54.

8. Silverstein E., Pertschuk L. P., Friedland J. Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas. Proceedings of the National Academy of Sciences of the United States of America. 1979; 12 (76): 6646–8.

9. DeRemee R.A., Lufkin E. G., Rohrbach M. S. Serum angiotensin-converting enzyme activity. Its use in the evaluation and management of hypercalcemia associated with sarcoidosis. Archives of internal medicine.1985; 4 (145): 677–9.

10. Khan A. H. [et al.]. Role of Serum Angiotensin Converting Enzyme in Sarcoidosis. Journal of Pakistan Medical Association. 1998; 48: 131–133.

11. Studdy P. R., Bird R. Serum Angiotensin Converting Enzyme in Sarcoidosis – Its Value in Present Clinical Practice. Annals of Clinical Biochemistry: An International Journal of Biochemistry and Laboratory Medicine. 1989; 1 (26): 13–18.

12. Chopra A., Kalkanis A., Judson M. A. Biomarkers in sarcoidosis. Expert Review of Clinical Immunology. 2016; 11(12): 1191–1208.

13. Csongrádi A. [et al.]. Optimized angiotensin-converting enzyme activity assay for the accurate diagnosis of sarcoidosis. Clinical Chemistry and Laboratory Medicine (CCLM). 2018; 7 (56): 1117–1125.

14. Ashutosh K., Keighley J. F. Diagnostic value of serum angiotensin converting enzyme activity in lung diseases. Thorax. 1976; 5 (31): 552–7.

15. Klech H. [et al.]. Assessment of activity in Sarcoidosis. Sensitivity and specificity of 67Gallium scintigraphy, serum ACE levels, chest roentgenography, and blood 137 lymphocyte subpopulations. Chest. 1982; 6 (82): 732–738.

16. Lavaud F. [et al.]. [Assay of angiotensin converting enzyme (ACE) in thoracic forms of sarcoidosis and other pulmonary diseases]. La Nouvelle Presse Medicale.1979; 45 (8): 3755.

17. Lieberman J. The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis. Annals of the New York Academy of Sciences. 1976; (278): 488–97.

18. Lieberman J. [et al.]. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67 gallium scans, chest roentgenograms, and pulmonary function. undefined. 1983. Sarcoidosis. Journal Of Pakistan Medical Association. 1998; 131–133.

19. Nosal A. [et al.]. Angiotensin-I–Converting Enzyme and Gallium Scan in Noninvasive Evaluation of Sarcoidosis. Annals of Internal Medicine.1979; 3 (90): 328.

20. Rohatgi P. K., Ryan J. W. Simple Radioassay for Measuring Serum Activity of Angiotensin-Converting Enzyme in Sarcoidosis. Chest.1980; 1 (78): 69–76.

21. Studdy P., Bird R., James D. G. Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders. Lancet (London, England). 1978; (2) 8104–5: 1331–4.

22. Studdy P. R., Bird R. Serum Angiotensin Converting Enzyme in Sarcoidosis – Its Value in Present Clinical Practice. Annals of Clinical Biochemistry: An International Journal of Biochemistry and Laboratory Medicine.1989; 1 (26): 13–18.

23. Ungprasert P. [et al.]. Diagnostic Utility of Angiotensin-Converting Enzyme in Sarcoidosis: A Population-Based Study. Lung.2016; 1 (194): 91–95.

24. Wenqiao Wang, Yue Ma, Yongming Zhang, Jie He, Ying Nong, et al. Diagnostic and staging value of serum angiotensin-converting enzyme in sarcoidosis. 03/22/2022. DOI: 10.1155/2022/4657502.

25. Chopra A., Kalkanis A., Judson M. A. Biomarkers in sarcoidosis. Expert Review of Clinical Immunology. 2016; 11 (12): 1191–1208.

26. Harper LJ, Gerke AK, Wang XF, et al. Income and other reasons for poor outcomes in patients with sarcoidosis in the United States. American Journal of Respiratory and Critical Care Medicine. 2020; 201 (8): 955–964. DOI: 10.1164/rccm.201906-1250OC

27. Eckle T., Koeppen M., Eltzschig H. K. Role of Extracellular Adenosine in Acute Lung Injury. Physiology. 2009; 24 (5): 298–306.

28. Aherne C. M., Kewley E. M., Eltzschig H. The resurgence of A2B adenosine receptor signaling. Bochim Biophys Acta. 2011; 1808 (5): 1329–1339.

29. Koeppen M., Eckle T., Eltzschig H. K. Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol. 2011; (61): 145–186.

30. Zhou Y., Schneider D. J., Blackburn M. R. Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther. 2009; (123), Issue 1: 105–116.

31. Novikova L. N., Garmash Yu. Yu., Ryzhov A. M. Clinical significance of monitoring the indicator of lipoidosis activity in sarcoidosis and tuberculosis. Collection. Scientific works (to the 80th anniversary of the birth of the Honored Scientist, Professor, Academician of the Russian Academy of Sciences V. I. Litvinov). Moscow. 2021; pp. 250–266.

32. Zhu S, Lv H, Shen J. JNK pathway-associated phosphatase as a serum marker of disease activity and treatment outcome in juvenile idiopathic arthritis. Tohoku Journal of Experimental Medicine. 2021; 253 (1): 19–28. DOI: 10.1620/tjem.253.19.

33. Chakrabarti R, Kapse B, Mukherjee G. Soluble immune checkpoint molecules: serum markers for cancer diagnosis and prognosis. Cancer Reports. 2019. 2. article el 160. DOI: 10.1002/cnr2.1160.

34. Garmash Yu. Yu., Novikova L. N., Ryzhov A. M. The role of lipids in the pathogenesis of inflammation in sarcoidosis. Medical Alphabet. 2017; 33 (330): 45–52.

35. Garmash Yu. Yu., Novikova L. N., Ryzhov A. M. Method for diagnosing endogenous inflammation in patients with sarcoidosis based on the activity of lipoidosis. Patent for invention 2731887. P. 1. 09.09.2020. Application No. 2020101292 dated 01/15/2020.

36. Garmash Yu. Yu., Novikova L. N., Ryzhov A. M. Method for diagnosing exacerbation of sarcoidosis. Patent for invention 2795365. P. 2. 03.05.2023. Application No. 2023103036 dated 02/10/2023.